Clinical trial
Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors
NCT02454972 · PharmaMar, Industry · Completed
Key facts
| NCT number | NCT02454972 |
|---|---|
| Title | Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors |
| Official title | A Multicenter Phase II Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors |
| Lead sponsor | PharmaMar, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Advanced Solid Tumors |
| Intervention type | Drug |
| Interventions | lurbinectedin (PM01183) |
| Enrollment | 345 |
| Start date | Aug 25, 2015 |
| Primary completion | Sep 18, 2020 |
| Completion | Sep 18, 2020 |
| First posted | May 27, 2015 |
| Last update posted | Mar 2, 2023 |
| Countries | Belgium, France, Germany, Italy, Spain, Sweden, Switzerland, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: